2. Signaling Pathways
  3. Anti-infection
  4. HBV

HBV

Hepatitis B virus

HBV

Related Products

PDF 0.42 MB

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-163581A
    HBV/HDV-IN-4 hydrochloride
    		Inhibitor
    HBV/HDV-IN-4 hydrochloride (Compd 4) is a dual HBV and HDV inhibitor, with an EC50 of <50 nM against HBV.
    HBV/HDV-IN-4 hydrochloride
  • HY-181347
    GLPG3808
    		Inhibitor
    GLPG3808 is an orally active PAPD5/7 inhibitor. GLPG3808 inhibits the expression of HBcAg in various cells infected with HBV. GLPG3808 reduces the hepatitis B surface antigen levels in HBV-infected animal models. GLPG3808 can be used for the research of hepatitis B virus infection.
    GLPG3808
  • HY-161604
    HBV/HDV-IN-1
    		Inhibitor
    HBV/HDV-IN-1 (Compd 122) is a HBV, HDV and PD-1/PD-L1 inhibitor, with EC50 values of 8 nM for T cell activation and 35 nM for PD-L1 internalization.
    HBV/HDV-IN-1
  • HY-163149
    AB-452
    		Inhibitor
    AB-452, a Dihydroquinolizinone (DHQ) analogue, is a potent and orally active HBV RNA destabilizer. AB-452 inhibits PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model.
    AB-452
  • HY-177625A
    Daplusiran sodium
    		Inhibitor
    Daplusiran sodium is a siRNA in JNJ-3989 (JNJ-73763989). JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.
    Daplusiran sodium
  • HY-N0056R
    Isochlorogenic acid A (Standard)
    		Inhibitor
    Isochlorogenic acid A (Standard) is the analytical standard of Isochlorogenic acid A. This product is intended for research and analytical applications. Isochlorogenic acid A (3,5-Dicaffeoylquinic acid) is a natural phenolic acid with anti-mutagenicity, anti-HBV, anti-HIV, anti-oxidant, anti-bacterial, and anti-inflammatoryy activities.
    Isochlorogenic acid A (Standard)
  • HY-174857
    HBeAg ligand 1
    		Inhibitor
    HBeAg ligand 1 (Compound S2) is a HBeAg inhibitor. HBeAg ligand 1 can be used for synthesis of PROTAC HBeAg degrader-1 (HY-174856).
    HBeAg ligand 1
  • HY-N2882
    Apigenin-4'-α-L-rhamnoside
    		Inhibitor
    Apigenin-4'-α-L-rhamnoside is a potent inhibitor of HBV. Apigenin-4'-α-L-rhamnoside inhibits the secretory level of HBV surface antigen (HBsAg) in HepG2.2.15 cells.
    Apigenin-4'-α-L-rhamnoside
  • HY-172835
    Rapavir
    		Inhibitor
    Rapavir (JH-B10) is a selective and potent sodium taurocholate cotransporting polypeptide (NTCP) inhibitor with an IC50 value of 1.8 nM for the uptake of taurocholic acid-d4 (TCA-d4). Rapavir exerts antiviral activity by directly binding to NTCP and blocking the entry of the virus into cells during the HBV infection phase. Rapavir is promising for research of HBV infections.
    Rapavir
  • HY-149435
    HBV-IN-36
    		Inhibitor
    HBV-IN-36 (compound 42) is a HBV inhibior (IC50=2 μM), showing anti-HBV activity with EC50 of 0.58 μM.
    HBV-IN-36
  • HY-148201
    Oleana-2,12-dien-28-oic acid
    		Inhibitor 99.88%
    Oleana-2,12-dien-28-oic acid is an HBV-DNA inhibitor, HBsAg and HBeAg inhibitor. Oleana-2,12-dien-28-oic acid can be used in hepatitis B virus infection disease research.
    Oleana-2,12-dien-28-oic acid
  • HY-144045
    HBV-IN-14
    		Inhibitor
    HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5).
    HBV-IN-14
  • HY-116001B
    (-)-Carbovir
    		Inhibitor 99.32%
    (-)-Carbovir is an active compound.
    (-)-Carbovir
  • HY-111073
    Bentysrepinine
    		Inhibitor
    Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields.
    Bentysrepinine
  • HY-145059
    HBV-IN-12
    		Inhibitor
    HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM＜EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15.
    HBV-IN-12
  • HY-147863
    HBV-IN-24
    		Inhibitor
    HBV-IN-24 (compound (2ʹS, 6S)-1a) is a potent HBV inhibitor. HBV-IN-24 exhibits potent inhibition activity against HBV DNA, HBsAg, and HBeAg, with EC50 values of 0.6, 0.6, and 4.6 nM, respectively. HBV-IN-24 shows excellent antiviral activity, could have improved neurotoxicity.
    HBV-IN-24
  • HY-146394
    HBV-IN-22
    		Inhibitor
    HBV-IN-22 (Compound LC5f) is an inhibitor of HBV DNA replication with IC50 values of 0.71 μM and 0.84 μM against wild-type and agent resistant HBV strains, respectively.
    HBV-IN-22
  • HY-179265
    D-CAM-14
    		Inhibitor
    D-CAM-14 is a potent HBV capsid assembly modulator with potent anti-HBV activity (EC50 = 0.1 nM, EC90 = 9 nM in HepAD38 cells). D-CAM-14 suppresses HBeAg, and HBcAg in HBV-infected HepG2-NTCP cells, with EC50 values of 98 and 67 nM, respectively. D-CAM-14 has distinct impacts on capsid radii and the morphology of preassembled capsids. D-CAM-14 can be used for HBV infection disease research.
    D-CAM-14
  • HY-113308AS2
    Taurolithocholic acid-d4-1 sodium
    		Inhibitor
    Taurolithocholic acid-d4-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
    Taurolithocholic acid-d<sub>4</sub>-1 sodium
  • HY-177625
    Daplusiran
    		Inhibitor
    Daplusiran is a siRNA in JNJ-3989 (JNJ-73763989). JNJ-3989 is comprised of 2 siRNAs (Daplusiran and Tomligisiran), that target hepatitis B virus (HBV) mRNAs for degradation, thereby inhibiting HBV replication.
    Daplusiran
Cat. No. Product Name / Synonyms Application Reactivity